
TRYVIO/JERAYGO Positioned To Redefine Treatment Of Resistant Hypertension Delveinsight
(MENAFN- PR Newswire) TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO, approved by the FDA in March 2024 and …